相关实验视频
Updated: Jun 4, 2025
08:10
The 6-hydroxydopamine Rat Model of Parkinson's Disease
Published on: October 27, 2021
10.5K
在甲基胺驱动的帕金森病中,HDAC6抑制剂载荷的大脑向的纳米载体介导的神经保护
Khang-Yen Pham1, Shristi Khanal2, Ganesh Bohara2
1Department of Biopharmaceutical Convergence, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Redox biology
|December 19, 2024
概括
这项研究开发了新型纳米颗粒,载有基脱乙酶6抑制剂 (CAY10603),用于治疗帕金森病. 工程纳米粒子有效地输送了药物,保护了脑细胞,并改善了疾病症状.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 帕金森病 (PD) 涉及破坏细胞乙化和α-synuclein积累.
- 基斯脱乙酶 (HDAC) 抑制剂为PD提供了潜在的治疗策略.
- CAY10603 (CAY),一种HDAC6抑制剂,由于溶解性差和半衰期短,具有局限性.
研究的目的:
- 为改善CAY10603.3的传递,设计装饰着乳酸的多分子 (乳酸与甘油酸) 纳米颗粒 (PLGA@CAY@Lf NPs).
- 在甲基胺 (Meth) 诱导的PD模型中评估PLGA@CAY@LfNP的疗效.
- 为了研究CAY载荷纳米粒子的神经保护机制.
主要方法:
- 装饰着乳酸的CAY装载PLGA纳米颗粒的配方.
- 对纳米粒子穿透血脑屏障和大脑积累的评估.
- 在甲基诱导的PD小鼠模型中评估治疗效果,包括生物化学和行为分析.
主要成果:
- PLGA@CAY@Lf NPs表现出增强的血脑屏障穿越和大脑积累.
- 纳米粒子传递的CAY恢复了乙化平衡,逆转了线粒体功能障碍,减少了氧化应激,并抑制了α-synuclein聚合.
- 在PD模型中,治疗使多巴胺水平正常化,减少神经炎症,改善行为缺陷.
结论:
- PLGA@CAY@Lf NPs代表了治疗帕金森病的有前途的药物输送系统.
- 通过改进纳米粒子传递来准HDAC6提供了一个可行的PD神经保护策略.
- 这种方法有可能用于治疗甲基胺诱导的神经毒性和帕金森病.
更多相关视频
相关概念视频
01:24Parkinson's Disease: Treatment
216
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
216
01:15Parkinson's Disease: Overview
476
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
476
01:29Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K